Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

Autor: Miguel Granell, Joaquín Martínez, Joan Bargay, Juan José Lahuerta, Raquel de Paz, Felipe de Arriba, Aurelio López, Maria Luisa Martin, Maria-Victoria Mateos, Rafael Martínez, Marta Valero, Albert Oriol, Francisco Javier Peñalver, Javier de la Rubia, Joan Bladé, Lorenzo Ji, Montserrat Perez, M Jesús Blanchard, Jose Luis Bello, Jesus San Miguel

Publikováno v: Leukemia Research Reports, Vol 4, Iss 2, Pp 64-69 (2015)
Leukemia Research Reports
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed85689515baddab0929faa6dd5724d9
https://doi.org/10.1016/j.lrr.2015.09.002

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Autor: Felipe de Arriba, Dolores Hernández, Joaquín Díaz-Mediavilla, Jesús F. San Miguel, Laura Rosiñol, Joan Bladé, Javier de la Rubia, Adrian Alegre, Miguel T. Hernandez, Yolanda González, Norma C. Gutiérrez, Etxebeste Mª Asunción, M Jesús Blanchard, Albert Oriol, Juan Besalduch, Maria-Victoria Mateos, Joaquin Martinez-Lopez, Ana Isabel Teruel, Huaibao Feng, Miquel Granell, Juan José Lahuerta, Luis Palomera, Helgi van de Velde

Publikováno v: Blood. 124:2108-2108

Background: Autologous stem-cell transplantation (ASCT) is the standard of care for younger patients with multiple myeloma (MM). The degree of tumor reduction after ASCT is the crucial factor associated with a prolonged PFS and OS, being the M-protei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2cf0a1927605bea3c7a9a798de76a00
https://doi.org/10.1182/blood.v124.21.2108.2108

Phase III Trial Of Bortezomib, Melphalan, and Prednisone (VMP) Versus Bortezomib, Thalidomide, and Prednisone (VTP) In Elderly Multiple Myeloma (MM) Patients: Update Follow-Up, Patterns Management Of First Relapse/Progression

Autor: Aurelio Lopez, Marta Valero, Jose Ignacio Lorenzo, Maria-Victoria Mateos, Albert Oriol, Martínez Joaquin, Montserrat Perez, Rafael Martinez, Raquel de Paz, Miguel Granell, Felipe De Arriba, M. Jesús Blanchard, Francisco Javier Peñalver, Jose Luis Bello, Maria Luisa Martin, Joan Bargay, Joan Blade, Juan Jose Lahuerta, Jesús F. San Miguel, Javier De La Rubia

Publikováno v: Blood. 122:1973-1973

Background Initial results of the Spanish GEM2005mas65 phase III trial comparing VMP versus VTP as induction therapy in elderly patients with newly diagnosed MM did not show any difference in terms of OS or PFS. The purpose of this study was to updat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f029abf8f13a83273267d45678d7ecfe
https://doi.org/10.1182/blood.v122.21.1973.1973

Prognostic Significance of the Lost of a Major Molecular Response In Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+CML)

Autor: M Jesús Blanchard, Javier Lopez, Maria Dolores Rey, J Valentin Garcia-Gutierrez, Marta Jimenez-Rolando, María Calbacho, Maria Tenorio, Pilar Herrera, Paloma Ramos, M.L.Martı́n Ramos

Publikováno v: Blood. 116:3435-3435

Abstract 3435 Background: Albeit of well-known, dramatic improvements, there remain some questions to be solved around Ph+CML in treatment with tyrosine kinase inhibitors (TKI). Among these, the significance of the amount of minimal residual disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aca585f7d34181de169a27a7bf20fb00
https://doi.org/10.1182/blood.v116.21.3435.3435

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

Autor: Luis Palomera, Juan Flores-Montero, María-Belén Vidriales, María José Calasanz, Josep Sarrá, Lourdes Cordón, Noemi Puig, Maria-Victoria Mateos, Maria Luisa Martin-Ramos, Jesús F. San Miguel, Laura Rosiñol, M Jesús Blanchard, Lucia Lopez-Anglada, Miguel T. Hernandez, Juan José Lahuerta, Norma C. Gutiérrez, Rafael Martínez, Jesús Martín, Joan Bladé, Albert Oriol, Javier de la Rubia, María Teresa Cedena, Ramón García-Sanz, Isabel Krsnik, J. Bargay, Bruno Paiva, Leire Burgos, José M. Moraleda, Joaquin Martinez-Lopez, Rafael Rios, Alberto Orfao

Publikováno v: Web of Science

Background: MRD is an established biomarker to evaluate treatment efficacy, define patients at risk based on persistent MRD, and eventually, act as surrogate for prolonged survival based on sensitive MRD-negative definitions. Accordingly, the IMWG ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f8f11fbe49931033ea889846f4ad9da
https://publons.com/wos-op/publon/20179665/